| Name | Ganciclovir sodium |
| Description | Ganciclovir sodium (Cytovene IV sodium) is the sodium salt of Ganciclovir with antiviral activity, especially against cytomegalovirus (CMV) and herpes simplex virus type 1 (HSV-1). |
| In vitro | Ganciclovir showed activity against feline herpesvirus type-1 (FHV-1, IC50 = 5.2 microM)[1]. |
| In vivo | In adult rats, the intracochlear diffusion of ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection. Counts of white blood cells, red blood cells and platelets decreased significantly in ganciclovir-treated newborn mice[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 40 mg/mL (144.29 mM)
DMSO : 3.06 mg/mL (10.98 mM), Sonication is recommended.
|
| Keywords | group | orally active | BW759 | inhibit | Nucleoside Antimetabolite/Analog | polymerase | CNS penetration | DNA | Ganciclovir sodium | serotype | BW 759 | Herpes simplex virus | Antibiotic | replication | herpes | HSV | Ganciclovir | BW-759 | infection | Inhibitor | viruse | CMV | Cytomegalovirus |
| Inhibitors Related | Stavudine | Rifampicin | 5-Fluorouracil | Metronidazole | L-Lysine | 2-Deoxy-D-glucose | Oxyresveratrol | 5-BrdU | Idoxuridine | Cytidine | Acyclovir | Chlorhexidine diacetate |
| Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
